ECSP11011541A - Antagonistas de la trayectoria hedgehog de ftalazina disustituida - Google Patents

Antagonistas de la trayectoria hedgehog de ftalazina disustituida

Info

Publication number
ECSP11011541A
ECSP11011541A EC2011011541A ECSP11011541A ECSP11011541A EC SP11011541 A ECSP11011541 A EC SP11011541A EC 2011011541 A EC2011011541 A EC 2011011541A EC SP11011541 A ECSP11011541 A EC SP11011541A EC SP11011541 A ECSP11011541 A EC SP11011541A
Authority
EC
Ecuador
Prior art keywords
antagonists
hedgehog
ftalazina
disttituted
trajectory
Prior art date
Application number
EC2011011541A
Other languages
English (en)
Spanish (es)
Inventor
Philip Arthur Hipskind
Takako Wilson
Bharvin Kumar Patel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP11011541A publication Critical patent/ECSP11011541A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EC2011011541A 2009-06-19 2011-12-16 Antagonistas de la trayectoria hedgehog de ftalazina disustituida ECSP11011541A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21862809P 2009-06-19 2009-06-19

Publications (1)

Publication Number Publication Date
ECSP11011541A true ECSP11011541A (es) 2012-01-31

Family

ID=42332981

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011541A ECSP11011541A (es) 2009-06-19 2011-12-16 Antagonistas de la trayectoria hedgehog de ftalazina disustituida

Country Status (36)

Country Link
US (2) US8273742B2 (e)
EP (1) EP2443104B1 (e)
JP (1) JP5596139B2 (e)
KR (1) KR101389165B1 (e)
CN (1) CN102459233B (e)
AR (1) AR077014A1 (e)
AU (1) AU2010260244B2 (e)
BR (1) BRPI1011601A2 (e)
CA (1) CA2764542C (e)
CL (1) CL2011003147A1 (e)
CO (1) CO6480932A2 (e)
CR (1) CR20110658A (e)
DK (1) DK2443104T3 (e)
DO (1) DOP2011000386A (e)
EA (1) EA019059B1 (e)
EC (1) ECSP11011541A (e)
ES (1) ES2409054T3 (e)
HK (1) HK1164872A1 (e)
HN (1) HN2011003139A (e)
HR (1) HRP20130408T1 (e)
IL (1) IL216599A (e)
JO (1) JO2931B1 (e)
MA (1) MA33363B1 (e)
MX (1) MX2011014029A (e)
MY (1) MY156667A (e)
NZ (1) NZ596882A (e)
PE (1) PE20121050A1 (e)
PL (1) PL2443104T3 (e)
PT (1) PT2443104E (e)
SG (1) SG177289A1 (e)
SI (1) SI2443104T1 (e)
TN (1) TN2011000627A1 (e)
TW (1) TWI385165B (e)
UA (1) UA106755C2 (e)
WO (1) WO2010147917A1 (e)
ZA (1) ZA201108587B (e)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723042A1 (en) * 2008-04-29 2009-11-05 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
DK2364185T3 (da) * 2008-11-03 2013-06-03 Lilly Co Eli Disubstituerede phthalazin-hedgehog-pathway-antagonister
EP2358703B1 (en) * 2008-11-17 2013-12-25 Eli Lilly and Company Tetrasubstituted pyridazines hedgehog pathway antagonists
PT2358698E (pt) 2008-11-17 2012-10-24 Lilly Co Eli Antagonistas da via hedgehog de piridazina tetrasubstituída
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
US9464079B2 (en) 2011-03-23 2016-10-11 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN105017140B (zh) * 2014-04-28 2017-12-29 复旦大学 邻氨基苯甲酰胺化合物及其制备方法和用途
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
CA2987067A1 (en) * 2015-06-05 2016-12-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
KR20230042756A (ko) 2016-03-15 2023-03-29 오리존 지노믹스 에스.에이. 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
CN106279114B (zh) * 2016-08-04 2019-01-29 东南大学 一种Taladegib的合成方法
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN106831718B (zh) * 2016-12-30 2019-05-07 上海科技大学 平滑受体配体及其应用
US11389434B2 (en) 2017-05-18 2022-07-19 Inserm Methods and pharmaceutical compositions for the treatment of mast cell diseases
CN115997122A (zh) 2020-06-26 2023-04-21 拉夸里亚创药株式会社 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物
KR20230107568A (ko) * 2020-10-13 2023-07-17 엔데버 바이오메디신스, 인크. 섬유증 치료 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (e) * 1977-06-03 1981-03-07 Pfizer
KR100443893B1 (ko) 1996-01-15 2004-10-15 얀센 파마슈티카 엔.브이. 혈관형성억제제피리다진아민
AU768130B2 (en) 1998-04-09 2003-12-04 Johns Hopkins University School Of Medicine, The Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
ES2233383T3 (es) 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
EP1482928B1 (en) * 2001-07-27 2009-09-23 Curis, Inc. Mediators of hedgehog signaling pathways,compositions and uses related thereto
CA2483311A1 (en) * 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
EA201890903A9 (ru) 2004-09-02 2021-11-10 Дженентек, Инк. Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
CA2681162C (en) * 2007-03-15 2015-11-24 Novartis Ag Benzyl and pyridine derivatives as modulators of hedgehog pathway
EP2170866B1 (en) * 2007-06-25 2014-08-13 Amgen Inc. Phthalazine compounds, compositions and methods of use
CA2697682A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inapropriate hedgehog signalling
CN101896472A (zh) * 2007-12-13 2010-11-24 锡耶纳生物技术股份公司 Hedgehog途径拮抗剂及其治疗应用
CA2723042A1 (en) * 2008-04-29 2009-11-05 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
WO2010017240A2 (en) * 2008-08-04 2010-02-11 Amgen Inc. Aurora kinase modulators and methods of use
DK2364185T3 (da) 2008-11-03 2013-06-03 Lilly Co Eli Disubstituerede phthalazin-hedgehog-pathway-antagonister
PT2358698E (pt) 2008-11-17 2012-10-24 Lilly Co Eli Antagonistas da via hedgehog de piridazina tetrasubstituída
EP2358703B1 (en) 2008-11-17 2013-12-25 Eli Lilly and Company Tetrasubstituted pyridazines hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
IL216599A (en) 2015-09-24
DK2443104T3 (da) 2013-05-06
BRPI1011601A2 (pt) 2016-03-22
WO2010147917A1 (en) 2010-12-23
NZ596882A (en) 2013-08-30
ZA201108587B (en) 2013-05-29
PT2443104E (pt) 2013-05-07
MA33363B1 (fr) 2012-06-01
EP2443104A1 (en) 2012-04-25
US8273742B2 (en) 2012-09-25
PL2443104T3 (pl) 2013-08-30
US20100324048A1 (en) 2010-12-23
JP2012530705A (ja) 2012-12-06
US9000023B2 (en) 2015-04-07
US20120316174A1 (en) 2012-12-13
ES2409054T3 (es) 2013-06-24
SG177289A1 (en) 2012-02-28
HRP20130408T1 (en) 2013-06-30
EA201270049A1 (ru) 2012-05-30
HK1164872A1 (en) 2012-09-28
CA2764542C (en) 2013-09-10
CN102459233B (zh) 2014-07-02
AU2010260244A1 (en) 2012-01-19
CA2764542A1 (en) 2010-12-23
TW201113268A (en) 2011-04-16
EP2443104B1 (en) 2013-04-17
CR20110658A (es) 2012-02-20
CO6480932A2 (es) 2012-07-16
TN2011000627A1 (en) 2013-05-24
SI2443104T1 (sl) 2013-07-31
AR077014A1 (es) 2011-07-27
KR101389165B1 (ko) 2014-04-24
PE20121050A1 (es) 2012-08-09
KR20120024783A (ko) 2012-03-14
HN2011003139A (es) 2013-07-29
EA019059B1 (ru) 2013-12-30
JP5596139B2 (ja) 2014-09-24
MY156667A (en) 2016-03-15
TWI385165B (zh) 2013-02-11
CN102459233A (zh) 2012-05-16
CL2011003147A1 (es) 2012-07-20
DOP2011000386A (es) 2012-02-29
MX2011014029A (es) 2012-02-21
AU2010260244B2 (en) 2013-09-05
JO2931B1 (en) 2015-09-15
UA106755C2 (uk) 2014-10-10
IL216599A0 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
ECSP11011541A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CR11741A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
HN2011002809A (es) Compuestos de vinil indazolilo
CR20120202A (es) Métodos y composiciones para tratar cáncer
EA200801758A1 (ru) Лекарственные формы, устойчивые к самовольному изменению
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MY153915A (en) Organic compounds
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
EA201170700A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
CL2011002967A1 (es) Compuestos derivados de 3-oxadiazolil-5-fenil-piperidina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamient y/o profilaxis de trastornos cardiovasculares, tromboembolicos y tumorales.
CL2008003931A1 (es) Compuestos derivados de n-fenil-imidazo-[1,2-a]-piridin-2-carboxamida sustituido; compuestos intermediarios; composicion farmaceutica; utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas, inflamatorias, epilepsia, osteoporosis, tumores malignos, entre otras.
EA200901613A1 (ru) Макроциклы и их применение
NZ609924A (en) Porphyrin treatment of neurodegenerative diseases
TN2010000489A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
CY1114078T1 (el) Ανταγωνιστες διυποκατεστημενης φθαλαζινης του μονοπατιου hedgehog
TN2010000583A1 (en) Organic compounds
CY1114071T1 (el) Ενωσεις βινυλοϊνδαζολυλιου
UA44477U (ru) Средство для лечения кролей при смешанной эймериозной инвазии